Phase 3Completed

A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Sponsor
Beijing InnoCare Pharma Tech Co., Ltd. (Industry)
Enrollment
3 enrolled
Conditions
Treatment-naїve Mantle Cell Lymphoma
Interventions
Orelabrutinib and R-CHOP; R-CHOP
Ages
adults, older adults
Registry
NCT05051891

Full record on ClinicalTrials.gov

From the registry

To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naїve mantle cell lymphoma.

Primary outcomes

  • PFS

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered